Skip to main content

Clinical Trials Using Lenalidomide

Review the clinical trials studying lenalidomide on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 26-50 of 72

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
Status: Active
Location: 5 locations
A Trial to Learn if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
Status: Active
Location: 3 locations
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Active
Location: 3 locations
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
Status: Active
Location: 4 locations
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Status: Active
Location: 3 locations
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone for the Treatment of Newly Diagnosed Multiple Myeloma
Status: Active
Location: 3 locations
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib
Status: Active
Location: 4 locations
A Study of Daratumumab
Status: Active
Location: 2 locations
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Status: Active
Location: 2 locations
Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma
Status: Active
Location: 2 locations
Glofitamab with Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients with Newly Diagnosed High Risk Mantle Cell Lymphoma
Status: Active
Location: 2 locations
Selinexor and Backbone Treatments of Multiple Myeloma Patients
Status: Active
Location: 7 locations
Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin With or Without Autologous Stem Cell Transplantation for the Treatment Relapsed or Refractory Multiple Myeloma or Newly Diagnosed, High Risk Multiple Myeloma
Status: Active
Location: 2 locations
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Status: Active
Location: 2 locations
Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
Status: Active
Location: Long Island Jewish Medical Center, New Hyde Park, New York
Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Tafasitamab and Lenalidomide as First Salvage Therapy for Relapsed or Refractory Large B-Cell Lymphoma after Axicabtagene Ciloleucel
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Isatuximab plus Lenalidomide After Autologous Hematopoietic Stem Cell Transplantation for Treatment of High-Risk Multiple Myeloma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Epcoritamab and Lenalidomide in Treating Patients with Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma
Status: Active
Location: Northwestern University, Chicago, Illinois
Tafasitamab in Combination with Lenalidomide and Rituximab for the Treatment of Follicular Lymphoma and Marginal Zone Lymphoma
Status: Active
Location: University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota
Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients with Minimal Residual Disease Positive after Stem Cell Transplant
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
Minimal Residual Disease Response after Completing Therapeutic Drug Regimen with Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma, MILESTONE Trial
Status: Active
Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide for the Treatment of Relapsed B-Cell Non-Hodgkin’s Lymphoma
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Talquetamab and Lenalidomide for Post Stem Cell Transplant Maintenance Therapy for Patients with Multiple Myeloma
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California